Literature DB >> 10542318

Polyethylenimine shows properties of interest for cystic fibrosis gene therapy.

S Ferrari1, A Pettenazzo, N Garbati, F Zacchello, J P Behr, M Scarpa.   

Abstract

Before being considered for a cystic fibrosis (CF) gene therapy trial, any gene delivery agent must be able to show that it produces low levels of toxicity as well as being able to protect the DNA from nuclease degradation. Here we show that complexes of linear polyethylenimine (L-PEI) and DNA can repeatedly be administered to animals (up to 21 consecutive days) without eliciting an immune response against PEI/DNA particles or inducing toxic side effects due to accumulation of PEI in the lungs. However, the host response to the exogenous protein resulted in some decrease of expression. PEI-mediated transfection was unaffected by treatment of the complexes with DNase (frequently used to reduce the viscosity of lung secretions in CF patients). Taken together, these properties make L-PEI a valuable vector for gene therapy of CF.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10542318     DOI: 10.1016/s0167-4781(99)00153-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  11 in total

Review 1.  Nucleic acid therapy for lifespan prolongation: present and future.

Authors:  Wing-Fu Lai
Journal:  J Biosci       Date:  2011-09       Impact factor: 1.826

2.  Formation of plasmid-based transfection complexes with an acid-labile cationic lipid: characterization of in vitro and in vivo gene transfer.

Authors:  Jeremy A Boomer; David H Thompson; Sean M Sullivan
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

3.  Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier.

Authors:  Jung Soo Suk; Anthony J Kim; Kanika Trehan; Craig S Schneider; Liudmila Cebotaru; Owen M Woodward; Nicholas J Boylan; Michael P Boyle; Samuel K Lai; William B Guggino; Justin Hanes
Journal:  J Control Release       Date:  2014-01-14       Impact factor: 9.776

4.  Formulation of a peptide nucleic acid based nucleic acid delivery construct.

Authors:  Peter G Millili; Daniel H Yin; Haihong Fan; Ulhas P Naik; Millicent O Sullivan
Journal:  Bioconjug Chem       Date:  2010-02-04       Impact factor: 4.774

5.  Inhibition of influenza virus production in virus-infected mice by RNA interference.

Authors:  Qing Ge; Lily Filip; Ailin Bai; Tam Nguyen; Herman N Eisen; Jianzhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-01       Impact factor: 11.205

6.  Design and synthesis of N4,N9-disubstituted spermines for non-viral siRNA delivery--structure-activity relationship studies of siFection efficiency versus toxicity.

Authors:  Moustafa K Soltan; Hassan M Ghonaim; Mohamed El Sadek; M Abou Kull; Lubna Abd El-aziz; Ian S Blagbrough
Journal:  Pharm Res       Date:  2008-10-09       Impact factor: 4.200

7.  Integrin binding angiopoietin-1 monomers reduce cardiac hypertrophy.

Authors:  Susan M Dallabrida; Nesreen S Ismail; Elke A Pravda; Emily M Parodi; Renee Dickie; Ellen M Durand; Jean Lai; Flavia Cassiola; Rick A Rogers; Maria A Rupnick
Journal:  FASEB J       Date:  2008-05-23       Impact factor: 5.191

8.  Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo.

Authors:  Achim Aigner
Journal:  J Biomed Biotechnol       Date:  2006

9.  Polyethylenimine-mediated gene delivery to the lung and therapeutic applications.

Authors:  Sante Di Gioia; Massimo Conese
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

Review 10.  Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology.

Authors:  Paul Zarogouldis; Nikos K Karamanos; Konstantinos Porpodis; Kalliopi Domvri; Haidong Huang; Wolfgang Hohenforst-Schimdt; Eugene P Goldberg; Konstantinos Zarogoulidis
Journal:  Int J Mol Sci       Date:  2012-08-29       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.